Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares were down 2.6% during trading on Tuesday . The stock traded as low as $64.87 and last traded at $65.82, with a volume of 198,133 shares traded. The stock had previously closed at $67.59.

Several research analysts recently commented on RARE shares. JMP Securities restated a “buy” rating and set a $84.00 target price (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 8th. Jefferies Group restated a “buy” rating and set a $109.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 8th. Credit Suisse Group AG restated a “buy” rating and set a $101.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 25th. Canaccord Genuity restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Finally, Leerink Swann restated a “buy” rating and set a $80.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Three analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $100.41.

The company has a 50-day moving average price of $57.01 and a 200-day moving average price of $61.41. The firm’s market cap is $2.59 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.02. During the same quarter last year, the company posted ($0.83) EPS. On average, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($5.88) EPS for the current year.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, July 15th. The shares were sold at an average price of $50.85, for a total transaction of $1,017,000.00. Following the transaction, the chief executive officer now directly owns 513,597 shares of the company’s stock, valued at approximately $26,116,407.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sunil Agarwal sold 650 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $66.00, for a total transaction of $42,900.00. Following the transaction, the insider now directly owns 7,111 shares in the company, valued at $469,326. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of the company. Trexquant Investment LP purchased a new position in Ultragenyx Pharmaceutical during the fourth quarter worth about $1,010,000. Dimensional Fund Advisors LP increased its position in Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock worth $6,414,000 after buying an additional 5,139 shares in the last quarter. Jennison Associates LLC increased its position in Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock worth $84,739,000 after buying an additional 109,724 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Ultragenyx Pharmaceutical by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 2,393,587 shares of the biopharmaceutical company’s stock worth $268,512,000 after buying an additional 275,497 shares in the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.